title: [Efficacy of estrogen-progestin replacement therapy after bone marrow transplantation].
abstract: Ovarian failure is a common consequence of chemotherapy and radiotherapy in women undergoing bone marrow transplantation. The longer survival in these women has raised, during the past years, the need for a better quality of life. The objective of the present study has been to evaluate perspectively the potential benefit of hormonal replacement therapy in 24 women who underwent bone marrow transplantation. The data obtained indicated that hormonal replacement therapy results effective in preventing and/or relieving the multiple manifestations of gonadal failure, including amenorrhea, hot flashes, atrophy of genital apparatus, osteoporosis and cardiovascular disease.
authors.affiliation: Clinica Ginecologica e Ostetrica, Ospedale SS. Annunziata, Università degli Studi G. d'Annunzio, Chieti.
authors.forename: U
authors.initials: U
authors.lastname: Bellati
authors.forename: E
authors.initials: E
authors.lastname: Iammarrone
authors.forename: P
authors.initials: P
authors.lastname: Bavaro
authors.forename: R D
authors.initials: RD
authors.lastname: Mattaeis
authors.forename: M
authors.initials: M
authors.lastname: Bizzarri
authors.forename: G
authors.initials: G
authors.lastname: Carabella
authors.forename: G
authors.initials: G
authors.lastname: Torlontano
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000628:therapy; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy; D007951:Leukemia, Myeloid / Q000628:therapy; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000628:therapy; D009436:Neural Tube Defects / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy; D055728:Primary Myelofibrosis / Q000628:therapy; D016649:Primary Ovarian Insufficiency / Q000517:prevention & control*; D045167:Progesterone Congeners / Q000627:therapeutic use; D011446:Prospective Studies; D017086:beta-Thalassemia / Q000628:therapy
chemical_list: D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate